The ASCO Post
  • News
  • Insights
  • Meetings
  • Multimedia
  • ASCO AI in Oncology
  • Subscribe
  • Search
  • AI in Oncology
  • Bladder Cancer
  • Breast Cancer
  • Cardio-oncology
  • CNS Cancers
  • Colorectal Cancer
  • Cost of Care
  • Infectious Diseases
  • Gastrointestinal Cancer
  • Genomics/Genetics
  • Geriatric Oncology
  • Global Cancer Care
  • Gynecologic Cancers
  • Head and Neck Cancer
  • Health-Care Policy
  • Hepatobiliary Cancer
  • Immunotherapy
  • Kidney Cancer
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Multiple Myeloma
  • Myelodysplastic Syndromes
  • Neuroendocrine Tumors
  • Pancreatic Cancer
  • Prostate Cancer
  • Sarcoma
  • Skin Cancer
  • Survivorship
  • Thyroid Cancer
  • Solid Tumors
  • Hematologic Malignancies
  • Issues in Oncology
Advertisement
  1. The ASCO Post
  2. CAR T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma: ZUMA-2
From the Journals News

CAR T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma: ZUMA-2

February 25, 2025
Share Share via Email Share on Facebook Share on LinkedIn Share on X
Advertisement
Advertisement

Related Content

Colorectal Cancer

ctDNA-Guided Treatment in Colorectal Cancer: Progress and Unanswered Questions

November 20

Circulating tumor DNA (ctDNA) testing can identify molecular residual disease in patients with colorectal cancer who have no radiographic evidence of cancer following curative-intent treatment. Although its prognostic value is well established, questions remain about how best to use the results to guide treatment.

Leukemia AI in Oncology

Could AI Benefit Access to Testing for Childhood Leukemia in Resource-Limited Settings?

November 20

Researchers in Mexico evaluated a machine-learning approach that uses targeted RNA sequencing to classify B-cell acute lymphoblastic leukemia into molecular subtypes—potentially offering a more accessible alternative to approaches that rely on whole-transcriptome sequencing.

Gynecologic Cancers Head and Neck Cancer

Understanding ctDNA Biology May Help Refine Liquid Biopsy Testing and Cancer Monitoring

November 20

Understanding the biology of ctDNA and matching testing methods to specific clinical needs will be essential to the use of liquid biopsies in cancer care, particularly as these tests become more sensitive, according to experts.

Issues in Oncology Genomics/Genetics

Expanding the Clinical Impact of Molecular Testing in Pediatric and AYA Cancers

November 20

The Somatic Profiling for Pediatric Cancer: Refining Our Understanding and Treatment (SPROUT) Working Group developed consensus recommendations to help clinicians determine which molecular tests to order for children, adolescents, and young adults with solid tumors.

Advertisement
The ASCO Post
  • Facebook
  • Linked In
  • X
Subscribe to newsletter

About

  • About The ASCO Post
  • Editorial Board
  • Disclosures
  • Disclaimer
  • Contact
  • Advertising
  • Privacy Policy
  • Your Privacy Choices

American Society of Clinical Oncology

  • ASCO website
  • ASCO AI in Oncology
Copyright © 2026 Conexiant unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.